Pembrolizumab for the treatment of diffuse large B-cell lymphoma
Pembrolizumab for the treatment of diffuse large B-cell lymphoma
复制标题
DOI：
10.1080/14712598.2019.1659777
复制
发表时间：
2019-08-30
影响因子：
4.6
通讯作者：
Kuruvilla, John
中科院分区：
文献类型：
--
作者：
Sheikh, Semira;Kuruvilla, John
简介：Pembrolizumab是一种新型单克隆抗体，靶向程序性细胞死亡蛋白1（PD-1）及其配体（PD-L1）之间的相互作用。派姆单抗在霍奇金淋巴瘤（HL）中显示出显著的临床疗效，但在非霍奇金淋巴瘤（NHL）中的结果好坏参半。一些NHL亚型与HL具有某些遗传特征，如染色体9p24.1的改变和PD-L1的表达，在早期试验中显示出有希望的缓解。涵盖的领域：在这篇综述中，我们提供了一个综述pembrolizumab作为一个化合物，并提出了现有的临床疗效和安全性数据在弥漫性大B细胞淋巴瘤的治疗。专家意见：目前的早期数据表明，单药派姆单抗治疗NHL显示出疗效和有利的安全性特征。然而，预计未来的治疗策略将是生物标志物驱动的，并将pembrolizumab纳入与化疗和/或免疫治疗药物的联合治疗。
Introduction: Pembrolizumab is a novel monoclonal antibody that targets the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1). Pembrolizumab has shown significant clinical efficacy in Hodgkin Lymphoma (HL), but results in non Hodgkin Lymphoma (NHL) are mixed. Some NHL subtypes, which share certain genetic features with HL, such as alterations in chromosome 9p24.1 and expression of PD-L1, have shown promising responses in early phase trials. Areas covered: In this review, we provide an overview of pembrolizumab as a compound, and present the available clinical efficacy and safety data in the treatment of diffuse large B cell lymphomas. Expert opinion: Current early phase data suggest that single agent pembrolizumab in NHL demonstrates both efficacy and a favorable safety profile. However, it is anticipated that future treatment strategies will be biomarker-driven and incorporate pembrolizumab into combination therapies with chemotherapy and/or immunotherapy agents.